Proven results for the treatment of canine otitis externa. Harnessing the potency of hydrocortisone aceponate (HCA), the broad-spectrum efficacy of gentamicin, and the consistent results of miconazole.
Important Safety Information
EASOTIC® (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Otic Suspension for Dogs: For otic (ear) use in dogs only. Contraindicated in dogs with known or suspected hypersensitivity to corticosteroids, imidazole antifungals, or aminoglycoside antibiotics. Do not use in dogs with known tympanic membrane (ear drum) perforation. The safe use of EASOTIC Otic Suspension in dogs used for breeding purposes has not been evaluated. Do not administer orally. Humans with known or suspected hypersensitivity to hydrocortisone, aminoglycoside antibiotics, or azole antifungals should not handle this product. For complete information or to obtain a package insert, contact Virbac at 1‐800‐338‐3659, or download here.
1. Rigaut D, Sanquer A, Maynard L, Reme CA. Efficacy of a topical ear formulation with a pump delivery system for the treatment of infectious otitis externa in dogs: a randomized controlled trial. Intern J Appl Res Vet Med. 2011;9(1):15–28.
2. Rey-Grobellet X, Rigaut D, Maynard L, Rème CA. Persistence of antimicrobials in the ear canal of dogs treated once daily for 5 days with 1 ml of a topical ear formulation. Virbac SA, Carros, F-06511 France; 2010.
3. Boda C, Liege P, Reme C. Evaluation of owner compliance with topical treatment of acute otitis externa in dogs: a comparative study of two auricular formulations. Intern J Appl Res Vet Med. 2011;9(2):157–165.
4. Lyskova P, Vydrzalova M, Mazurova J. Identification and antimicrobial susceptibility of bacteria and yeasts isolated from healthy dogs and dogs with otitis externa. J Vet Med. 2007;A54:559–563.
5. Schackert C, Korting HC, Schäfer-Körting M. Qualitative and quantitative assessment of the benefit/risk ratio of medium potency topical corticosteroids in vitro and in vivo. BioDrugs. 2000;13(4):267–277.
6. Hariharan,Harry, McPhee, Lynn, Heaney,Susan, Bryenton, James; Antimicrobial drug susceptibility of clinical isolates of Pseudomanas aeruginosa. Can Vet J 1995; 36:166-168
7. Guaguere E, Bensignor E, Carlotti DN, et al. Clinical practice guidelines on the best use of topical glucocorticoids in canine dermatology. Prat Med Chir Anim Comp. 2011;46:S1–S20.
8. Strain GM, Merchant SR, Neer TM, Tedford BL. Ototoxity assessment of a gentamicin sulfate otic preparation in dogs. Am J Vet Res. 1995;56:532–538.
9. Barasch,Andrei, Griffin, Andreea Voinea. Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials
10. Schäfer-Körting M, Gysler A. Topical glucocorticoids with improved benefit/risk ratio. In: Korting HC, Schäfer-Körting M, eds. The Benefit/Risk Ratio: A Handbook for The Rational Use of Potentially Hazardous Drugs. Boca Raton, FL: CRC Press; 1999:359–372.
ACTIVE INGREDIENTS: Contains 1.11 mg/mL hydrocortisone aceponate, 17.4 mg/mL miconazole nitrate, and 1.5 mg/mL gentamicin (as sulfate).